Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.

  title={Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-na{\"i}ve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.},
  author={Bertrand F Tombal and Michael Borre and Per Zier Rathenborg and Patrick Werbrouck and Hendrik van Poppel and Axel Heidenreich and Peter Iversen and Johan G. Braeckman and Jiř{\'i} Her{\'a}{\vc}ek and Edwina S Baskin-Bey and Taoufik Ouatas and Frank G Perabo and De H Phung and Beno{\^i}t Baron and Mohammad Hirmand and Matthew Raymond Smith},
  journal={European urology},
  volume={68 5},
BACKGROUND Enzalutamide is an androgen receptor inhibitor with a demonstrated overall survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of enzalutamide monotherapy in patients with hormone-naïve prostate cancer (HNPC) showed a high response rate for the prespecified primary endpoint (ie, prostate-specific antigen [PSA] response at week 25), regardless of metastases at baseline, and favorable tolerability. OBJECTIVE To determine the long-term efficacy and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 27 times over the past 90 days. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 27 references

Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial Please cite this article in press

  • ED Crawford, ND Shore, JW Moul
  • Urology
  • 2014
1 Excerpt

Increasedsurvivalwith enzalutamidein prostatecancerafter chemotherapy

  • HI Scher, K Fizazi, SaadF, etal
  • N Engl J Med
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…